Share Name Share Symbol Market Type Share ISIN Share Description
Bayer Ord LSE:BYR London Ordinary Share DE000BAY0017 REG SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00 € +0.00% 55.93 € 0.00 € 0.00 € - - - 0.00 05:00:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Chemicals 35,088.0 1,721.0 170.0 32.9 42,749.24

Bayer Ord Share Discussion Threads

Showing 26 to 41 of 50 messages
Chat Pages: 2  1
DateSubjectAuthorDiscuss
01/7/2008
04:57
Bayer "buy," target price raised 06/30/08 - Deutsche Bank LONDON, June 30 (newratings.com) - Analyst Tim Jones of Deutsche Bank maintains his "buy" rating on Bayer AG (BAY). The target price has been raised from €67 to €69. In a research note published this morning, the analyst mentions that a majority of the company's businesses present robust growth prospects. The industry outlook for the CropScience business is extremely healthy in the foreseeable future, aided by demand growth and price increases, the analyst adds. Potentially significant newsflow is expected regarding the development of the pharmaceutical pipeline in Bayer's Healthcare in the next six-to-eighteen months, Deutsche Bank says.
waldron
14/2/2008
10:43
Bayer warns of liver damage risk linked to Avelox antibiotic, changes label LEVERKUSEN, Germany (Thomson Financial) - Bayer AG has warned doctors that its Avelox antibiotic may lead to potentially fatal liver damage and skin disease in rare cases, following a routine analysis of recent data on side effects. The link between Avelox and the side effects has been known but the analysis has yielded very rare new cases, prompting the German drug maker to adjust the labelling of Avelox and informing doctors, a Bayer spokeswoman said, confirming a report in Dutch newspaper Algemeen Dagblad. Avelox, sold under the name of Avalox in Germany, is used to treat respiratory and other infections and generated 396 mln eur in sales in 2006. ludwig.burger@thomson.com lb/ra
ariane
09/12/2007
09:07
J&J, Bayer Pill Caused Fewer Clots Than Sanofi Drug in Study By Lisa Rapaport and Luke Timmerman Dec. 8 (Bloomberg) -- Bayer AG and Johnson & Johnson's experimental blood thinner led to fewer clots and deaths in patients after hip surgery than a widely used therapy sold by Sanofi-Aventis SA, a study found. About 1.1 percent of patients had serious blood clots or died on the Bayer and J&J pill, rivaroxaban, compared with 3.7 percent of those taking Sanofi's injected medicine, Lovenox, according to research reported today at the American Society of Hematology meeting in Atlanta. Both drugs had similar rates of bleeding, a side effect of anti-clotting medications. Rivaroxaban may help J&J and Bayer take market share from the injectable Lovenox, Sanofi's best-seller with $3.5 billion in sales last year. Bayer, Germany's largest drugmaker, asked European regulators to allow sale of the drug under the brand name Xarelto in October, and has projected peak sales of $2.9 billion. J&J, of New Brunswick, New Jersey, has said it will seek U.S. marketing approval in the second half of 2008. ``The results were quite astonishing,'' said Bengt Eriksson, an orthopedic surgeon at Sahlgrenska University Hospital in Gothenburg, Sweden, and the study's lead author, in an interview. ``It was a big surprise,'' for the new drug to demonstrate superior effectiveness, instead of merely showing about equal effectiveness, he said. Patients were given either Lovenox or rivaroxaban for five weeks after hip-replacements. Studies of the J&J and Bayer drug in other major orthopedic surgery will be presented Monday. Dangerous Clots Blood clots are usually part of the body's healing mechanism. If they form in one of the veins deep in the body, like those in the legs, the jelly-like mass can block blood flow causing the leg to swell. If a clot breaks lose, it can travel to the lungs or brain, a life-threatening situation. Around 300,000 Americans die every year from these clots, more than the number who die from AIDS, breast cancer and car accidents combined, according to the American Society of Hematology. ``This drug was measured against Lovenox, which is the gold standard, and we got more efficacy without paying a price in terms of any extra bleeding,'' said Lloyd Haskell, a vice president at J&J's pharmaceutical research and development unit, in a telephone interview. If approved by regulators, rivaroxaban will be marketed by J&J in the U.S. and by Bayer in the rest of the world. To contact the reporter on this story: Lisa Rapaport in New York at Lrapaport1@bloomberg.net Last Updated: December 8, 2007 11:14 EST
ariane
07/11/2007
17:49
Bayer "buy," target price raised - update Wednesday, November 07, 2007 9:04:44 AM ET Dresdner Kleinwort Wasser. LONDON, November 7 (newratings.com) - Analysts at Dresdner Kleinwort maintain their "buy" rating on Bayer AG (BAY.ETR), while raising his estimates for the company. The 12-month target price has been raised from €67 to €70. In a research note published this morning, the analysts mention that the company's CropScience division posted robust sales and margins for 3Q. Bayer's key products in the Healthcare division, Nexavar, Betaferon and Yasmin, posted robust results for the three-month period, with disappointing sales of women's health product, Trasylol, and diagnostic imaging, the analysts say. The diluted EPS estimates for 2007, 2008 and 2009 have been raised from €4.61 to €4.76, from €4.23 to €4.32 and from €4.80 to €5.03, respectively.
waldron
06/11/2007
11:00
Bayer Ag Bayer Q3 pre-ex EBITDA beats consensus as Schering outperforms UPDATE (Recasts intro, adds details on projected dividend, number of jobs cut) LEVERKUSEN, Germany (Thomson Financial) - Bayer AG said EBITDA before one-time charges rose 6.9 pct to 1.559 bln eur, up from a restated 1.459 bln last year, helped by higher sales of the Yasmin and Mirena contraceptives, acquired as part of the takeover of rival Schering. This surpassed the 1.546 bln eur average estimate compiled in a Thomson Financial News survey of seven analysts. Third-quarter revenue advanced 4.5 pct to 7.793 bln eur, compared with an average analyst forecast of 7.764 bln. "Not least because of the Schering acquisition, we have enhanced our earnings power (in the long term)," chief executive Werner Wenning said. "The results were solid," said Martin Brunninger, an analyst at Cazenove in London. "But once again the main profit contributors and growth drivers were Schering products and pharmaceuticals from the traditional Bayer business were very disappointing." Bayer last year bought rival German drug maker Schering for 17 bln eur. Yasmin generated 35 pct more revenue than last year, while the rate was 29.7 pct for Mirena, the two fastest growing drugs among the company's 10 best selling pharmaceuticals. Brunning also pointed to Trasylol, an injection to prevent excessive blood loss during surgery which Bayer yesterday temporarily pulled off global markets because of reported side-effects. Trasylol is part of Bayer's traditional business, as is the Cipro antibiotic, which saw a loss in sales of 17.9 pct in the third quarter. Bayer recalculated last year's figure to exclude sold businesses such as H.C. Starck and Wolff Walsrode. The German company also said it expects the 2007 margin of EBITDA before one-time charges over sales to reach at least 20.3 pct, up from 19.3 pct last year. Chief executive Wenning has declared EBITDA before one-time charges as a percentage of sales Bayer's yardstick of success, having said previously the margin is set to exceed 20 pct this year and rise above 22 pct by 2009. The full-year sales target was also increased, to more than 32 bln eur, a gain of about 6 pct when excluding the effect of portfolio changes and currency swings and higher than the earlier comparable goal of an about 5 pct rise. Quarterly revenue at the HealthCare unit, Bayer's largest, rose 5.7 pct to 3.680 bln. The company sees the 2007 pre-exceptional EBITDA margin at the division, whose products range from the Aspirin painkiller to blood-clotting drug Kogenate and the Betaferon multiple sclerosis injection, at more than 25 pct. The previous goal was to reach 25 pct. Wenning said he deems the experimental anti-thrombosis pill Xarelto Bayer's most promising product, saying it has "blockbuster potential". In addition to the four uses Xarelto is being tested for, a further indication for hospitalised patients with internal diseases will be pursued. Other drugs that will drive the unit's expansion include the Nexavar kidney cancer treatment, which was recently cleared to treat liver cancer patients in Europe as well. Bayer's CropScience unit posted a 10.3 pct revenue gain on strong demand for pesticides in Latin America. Pre-exceptional EBITDA jumped 16.8 pct to 167 mln eur at the unit, "due largely to higher volumes", the company said. The company-wide net profit soared to 1.175 bln eur, up from 320 mln eur last year on tax effects. Bayer had earlier said it would free up 900 mln eur in the third quarter money set aside for future tax liabilities because of a cut in the corporate tax rate next year. Bayer also said it plans to restructure its MaterialScience unit and to cut jobs there to save 300 mln eur a year by the end of 2009. This will prompt total special charges of 150 mln eur to 200 mln in 2008 and 2009, it added. Job cuts, 400 to 500 in total, will be pursued in a "socially compatible way and through normal attrition", and should be achieved without redundancies, Wenning said. The dividend paid out for 2007 will be "based" on 30 pct to 40 pct of full-year core earnings per share, a profit measure that excludes discontinued operations and write-downs and integration costs related to the Schering takeover, Bayer said. ludwig.burger@thomson.com lb/slj/lb/wj
waldron
06/11/2007
07:30
Bayer Ag Bayer Q3 pre-ex EBITDA rises 6.9 pct to 1.559 bln, beating consensus UPDATE (Adds full-year sales target, restructuring at MaterialScience unit) LEVERKUSEN, Germany (Thomson Financial) - Bayer AG said third quarter EBITDA before one-time charges rose 6.9 pct to 1.559 bln eur, up from a restated 1.459 bln last year, on higher sales at its pharmaceuticals division and strong demand for farming pesticides. That surpassed the 1.546 bln eur average estimate in a Thomson Financial News survey of seven analysts. Third quarter revenue advanced 4.5 pct to 7.793 bln eur, compared with an average analyst forecast of 7.764 bln. Bayer also said it expects the 2007 EBITDA margin before one-time charges over sales to reach at least 20.3 pct, up from 19.3 pct last year. Chief executive Werner Wenning has declared EBITDA before one-time charges as a percentage of sales as Bayer's yardstick of success, saying previously that the margin is set to exceed 20 pct this year and rise above 22 pct by 2009. The company now aims for full-year sales to reach more than 32 bln eur, equivalent to a gain of about 6 pct when excluding the effect of portfolio changes and currency swings, which is more than the earlier comparable target of a gain of about 5 pct. Bayer also said it plans to restructure its MaterialScience unit and to cut jobs there to save 300 mln eur annually by the end of 2009. This will prompt total special charges of 150 mln eur to 200 mln through 2009, it added. The company plans to pursue the job cuts in a socially compatible way and through normal attrition, it said, without specifying the number of jobs affected. ludwig.burger@thomson.com lb/lam/lb/cw
waldron
05/11/2007
11:50
Bayer to temporarily suspend sale of Trasylol worldwide LEVERKUSEN, Germany (Thomson Financial) - Bayer AG said it will temporarily suspend selling the blood-clotting injection Trasylol worldwide, after a study in Canada was interrupted last month because experts said the drug exposed trial participants to an increased risk of death. The drug, given before coronary bypass surgery to prevent excessive blood loss, will not be sold until data from the study, known as BART, is fully analysed, the company said in a statement today. The global suspension follows a "direction" from German regulators to suspend the marketing of Trasylol in Germany and a "request" from the US Food and Drug Administration to suspend marketing of the product in the US, Bayer said. ludwig.burger@thomson.com lb/cmr
waldron
26/10/2007
13:24
Bayer "overweight," target price raised Friday, October 26, 2007 8:49:24 AM ET J.P. Morgan Securities LONDON, October 26 (newratings.com) - Analysts at JP Morgan reiterate their "overweight" rating on Bayer AG (BAY.ETR), while raising their estimates for the company. The 12-month target price has been raised from €70 to €73. In a research note published this morning, the analysts mention that there is a 60% probability of the company's Rivaroxaban product achieving peak sales of €5 billion. Bayer's share price is expected to be supported by the improved outlook for the Consumer Health division, oral contraceptives and Kogenate margins, the analysts say. The EPS estimates for 2007 and 2008 have been raised from €3.81 to €3.82 and from €4.19 to €4.21, respectively.
grupo guitarlumber
12/10/2007
08:59
Merck Kgaa Bayer, Genzyme to release new Phase II results on alemtuzumab in MS patients CAMBRIDGE, MA (Thomson Financial) - Bayer AG and Genzyme Corp will publish this weekend "important" new data on the use of leukemia drug alemtuzumab, which they are jointly developing, in multiple sclerosis (MS) patients, according to Genzyme. The results of a concluded three-year phase II study involving 334 relapsing-remitting MS patients will be presented at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Prague on Oct 14, the US biotech company said in a statement. The companies in May said interim results based on the first two years of the three-year phase II trial indicated that the drug led to fewer relapses and was better at slowing the progression of disabilities than Merck KGaA's Rebif. Bayer and Genzyme last month said they have already started testing the compound on relapsing-remitting MS patients in the third and last phase of clinical trials required for regulatory approval of the new use. Alemtuzumab is also the active compound in Bayer's Campath leukemia drug. The German drugmaker owns the exclusive rights to market and distribute the ingredient. ludwig.burger@thomson.com lb/mas/ak
ariane
09/10/2007
08:54
Bayer Ag Bayer wins contract to build waste water facility in Israel LEVERKUSEN, Germany (Thomson Financial) - Bayer AG said its Technology Services division won a contract from Makhteshim Chemical Workers to build a waste water facility in Israel. No financial details were disclosed. Bayer said the facility will be the the biggest to date based on its Loprox process, which pre-treats highly polluted water prior to biological waste water treatment. judith.csaba@thomson.com jcs/rfw
ariane
26/9/2007
13:15
Bayer, Genzyme start phase 3 testing of alemtuzumab on MS patients LEVERKUSEN, Germany (Thomson Financial) - Bayer AG and its development partner Genzyme Corp have started testing their alemtuzumab leukemia drug on multiple sclerosis (MS) patients in the last phase of clinical trials required for regulatory approval of the new use. Alemtuzumab, the active compound in Bayer's Campath leukemia drug, is being tested against Merck KGaG's Rebif as a first treatment in patients with newly diagnosed relapsing-remitting MS, Bayer said in a statement today. Bayer, through its Bayer Schering Pharma division, owns the exclusive rights to market and distribute the compound. ludwig.burger@thomson.com lb/dca
ariane
18/9/2007
19:11
Shorter TB therapy shows promise Date : 18/09/2007 @ 20:05 Source : TFN Shorter TB therapy shows promise CHICAGO (AP) - New research gives hope for successfully treating tuberculosis in a few months rather than the six months or more currently needed to beat the contagious lung disease, doctors reported Tuesday. Adding the antibiotic moxifloxacin to the usual TB drugs shortened the time to cure to an estimated four months in a study in Brazil, Johns Hopkins University scientists reported at an American Society for Microbiology conference in Chicago. A second study by Hopkins researchers cured mice of TB in 10 weeks instead of the usual six months with moxifloxacin plus the TB drug rifapentine at higher doses. "It sounds fantastic," said Dr. Melvin Spigelman, research and development director for the nonprofit Global Alliance for TB Drug Development in New York. "The science is there" and just needs to be verified in larger studies, he said. The group will launch a 2,400-patient study later this year. Also on Tuesday, the Seattle-based Bill & Melinda Gates Foundation announced its largest grants ever to fight TB -- $280 million for research on vaccines, diagnostics and drugs. "If everything goes well, it should be feasible to shorten treatment time," possibly even to ultra-short regimens of two weeks to a month, said Ken Duncan, the foundation's program director. More than 8 million people worldwide develop TB each year and nearly 2 million die of it. The disease is mostly a problem in poor countries, but the recent case of Andrew Speaker, an Atlanta attorney who created an international health scare by traveling while he had a multidrug-resistant strain of TB, shows the danger in the United States as well. Recently, a Mexican teenager was jailed in Georgia and threatened with deportation after refusing to take his recommended nine months of TB treatment. Similar cases have surfaced around the country. Treatment now consists of three or four antibiotics taken daily for six months or more. But half of patients do not take all their pills, allowing resistant bacteria to grow and spread, said Dr. Jacques Grosset, the Hopkins researcher who led the study of several hundred mice. The Brazil study involved about 170 men and women in Rio de Janeiro who had active TB. All were given three standard anti-TB drugs plus either moxifloxacin or an older drug, ethambutol. After two months, 85 percent of those on moxifloxacin tested negative for the infection compared to 68 percent on ethambutol. The treatment advantage showed up in as little as two weeks. "Based on what we know, if you get that big a difference at two months, you should be able to shorten the duration of treatment ... down to four," said Dr. Richard Chaisson, director of TB research at Hopkins. In a third study of about 400 TB patients throughout Africa, 60 percent who received moxifloxacin plus three other drugs tested negative for TB at two months versus 55 percent given isoniazid and the other medications. The federal government paid for the studies, and Bayer Healthcare AG donated moxifloxacin, which it sells as Avelox in the United States for short-term use against pneumonia and other respiratory illnesses. The pill costs $10 a day, but researchers said Bayer has promised to make it available in poor countries for less if it is approved to treat TB.
ariane
17/9/2007
09:48
Bayer Ag Novartis CEO rules out major pharma merger; no comment on Bayer buy speculation ZURICH (Thomson Financial) - Novartis AG chief executive Daniel Vasella has ruled out a merger of major players in the pharmaceutical market, while again declining to comment on rumours linking the company with a takeover of German rival Bayer AG. In an interview with French economic newspaper La Tribune, he said he has "no indication that could confirm the rumours of a merger between major players" in the sector. In the case of Novartis, he pointed out that investments in R&D has grown some 90 pct since 2002. That is faster than revenue growth, and is "not sustainable", he said. However, a merger is "not the answer", he added. "It would be an error to just base any acquisitions on the price," he said, adding that the company has to make sure that it meets its quality criteria and it can build on it. Asked about recent market speculation linking the Swiss pharma group with a bid for German rival Bayer, Vasella once again declined to comment. The Basel-based drug maker has been hit by the suspension of constipation drug Zelnorm as well as by generic competition for some of its key drugs. But last Wednesday, Novartis has projected that it should return to "strong" growth territory by the second half of 2008, including double-digit growth for the phamarceuticals division. Huimin.neo@thomson.com at/hmn/ra
ariane
15/9/2007
05:16
Bayer initiated with "outperform" Friday, September 14, 2007 10:21:29 AM ET Bear Stearns LONDON, September 14 (newratings.com) - Analyst Richard Vosser of Bear Stearns reinitiates coverage of Bayer AG (BAY.ETR) with an "outperform" rating. The target price is set to €75. In a research note published this morning, the analyst mentions that the company's Healthcare business is expected to generate 18.9% EPS growth in 2007-2011 and is unlikely to reach an earnings trough up to 2015. Despite the high quality of the Healthcare business, Bayer's share price reflects the value of this business in-line with that of the European large-cap pharma peers, the analyst says. While Xarelto has the potential to become a multi-billion euro product over the next ten years, Nexavar may become a blockbuster in liver cancer, Bear Stearns adds.
ariane
09/9/2007
09:30
http://www.bayer.com/en/Homepage.aspx
ariane
09/9/2007
09:25
Bayer "buy" Tuesday, September 04, 2007 7:19:03 AM ET Dresdner Kleinwort Wasser. LONDON, September 4 (newratings.com) - Analyst Tero Weckroth of Dresdner Kleinwort maintains his "buy" rating on Bayer (BAY.ETR). The target price is set to €67. In a research note published this morning, the analyst mentions that the company's recent management roadshow was encouraging. Despite the 43% appreciation in Bayer's share price year-to-date, the current valuation of the company's stock is attractive, the analyst adds.
ariane
Chat Pages: 2  1
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V: D:20161203 02:29:54